208 results on '"Chretien, Marie‐Lorraine"'
Search Results
2. Daratumumab, carfilzomib, lenalidomide, and dexamethasone with tandem transplant for high-risk newly diagnosed myeloma
3. Gilteritinib activity in refractory or relapsed FLT3-mutated acute myeloid leukemia patients previously treated by intensive chemotherapy and midostaurin: a study from the French AML Intergroup ALFA/FILO
4. Biallelic deletion of 1p32 defines ultra-high-risk myeloma, but monoallelic del(1p32) remains a strong prognostic factor
5. Carfilzomib maintenance in newly diagnosed non-transplant eligible multiple myeloma
6. Bortezomib and high-dose melphalan conditioning regimen in frontline multiple myeloma: an IFM randomized phase 3 study
7. Primary plasma cell leukemias displaying t(11;14) have specific genomic, transcriptional, and clinical features
8. Daratumumab Carfilzomib Lenalidomide and Dexamethasone with tandem transplant in high-risk newly diagnosed myeloma
9. Access to optimal treatment of acute myeloid leukaemia patients is affected by sociodemographic factors: a French population based-study.
10. Early Chimeric Antigen Receptor T Cell Expansion Is Associated with Prolonged Progression-Free Survival for Patients with Relapsed/Refractory Multiple Myeloma Treated with Ide-Cel: A Retrospective Monocentric Study
11. Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma
12. Ponatinib evaluation and safety in real-life chronic myelogenous leukemia patients failing more than two tyrosine kinase inhibitors: the PEARL observational study
13. PB1855: USE OF MACHINE LEARNING MODEL TO IDENTIFY PATIENTS RECEIVING OPTIMAL TREATMENT AND THE ASSOCIATED NON-BIOLOGICAL FACTORS: A POPULATION-BASED STUDY
14. Serum free light chains, not urine specimens, should be used to evaluate response in light-chain multiple myeloma
15. Extending autologous transplantation as first line therapy in multiple myeloma patients with severe renal impairment: a retrospective study by the SFGM-TC
16. In Multiple Myeloma, High-Risk Secondary Genetic Events Observed at Relapse Are Present From Diagnosis in Tiny, Undetectable Subclonal Populations
17. Understanding the role of hyperdiploidy in myeloma prognosis: which trisomies really matter?
18. Factors influencing access to specialised haematology units during acute myeloblastic leukaemia patient care: A population‐based study in France
19. Role of additional chromosomal changes in the prognostic value of t(4;14) and del(17p) in multiple myeloma: the IFM experience
20. Nosocomial infections with IMP-19-producing Pseudomonas aeruginosa linked to contaminated sinks, France
21. Gilteritinib Activity in Refractory or Relapsed FLT3-Mutated Acute Myeloid Leukemia Patients Previously Treated By Intensive Chemotherapy and Midostaurin: A Study from the French AML Intergroup ALFA/Filo
22. Heterogeneity in long term outcomes for R-ISS stage II in newly diagnosed multiple myeloma patients
23. Tif1γ regulates the TGF-β1 receptor and promotes physiological aging of hematopoietic stem cells
24. OAB-041: Daratumumab carfilzomib lenalidomide and dexamethasone as induction therapy in high-risk transplant eligible newly diagnosed myeloma patients: results of the phase 2 study IFM 2018-04
25. OAB-016: High risk subclones detected at relapse are present from diagnosis in small subclones and impact the prognosis
26. Mortality and Major Cardiovascular Events among Patients with Multiple Myeloma: Analysis from a Nationwide French Medical Information Database
27. Evolution of procalcitonin, C-reactive protein and fibrinogen levels in neutropenic leukaemia patients with invasive pulmonary aspergillosis or mucormycosis
28. All-oral triplet combination with ixazomib, lenalidomide, and dexamethasone in newly diagnosed transplant-eligible myeloma patients: final results of the phase 2 IFM study 2013-06
29. All-oral triplet combination of ixazomib, lenalidomide, and dexamethasone in newly diagnosed transplant-eligible multiple myeloma patients: final results of the phase II IFM 2013-06 study
30. Trends in autologous stem cell transplantation for newly diagnosed multiple myeloma: Changing demographics and outcomes in European Society for Blood and Marrow Transplantation centres from 1995 to 2019
31. In Multiple Myeloma, High-Risk Secondary Genetic Events Observed at Relapse Are Present from the Diagnosis in Tiny Undetectable Subclones
32. Daratumumab Plus Ixazomib, Lenalidomide, and Dexamethasone As Extended Induction and Consolidation Followed By Lenalidomide Maintenance in Standard-Risk Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM) Patients (IFM 2018-01): A Phase II Study of the Intergroupe Francophone Du Myélome (IFM)
33. Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone Induction and Consolidation with Tandem Transplant in High-Risk Newly Diagnosed Myeloma Patients: Final Results of the Phase 2 Study IFM 2018-04
34. Self‐management of immunomodulatory drug treatment in multiple myeloma patients
35. Daratumumab and dexamethasone is safe and effective for triple refractory myeloma patients: final results of the IFM 2014-04 (Etoile du Nord) trial
36. Development and Validation of a Cytogenetic Prognostic Index Predicting Survival in Multiple Myeloma
37. Adherence to immunomodulatory drugs in patients with multiple myeloma
38. Gilteritinib activity in refractory or relapsed FLT3-mutated acute myeloid leukemia patients previously treated by intensive chemotherapy and midostaurin: a study from the French AML Intergroup ALFA/FILO
39. Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma.
40. Self‐management of immunomodulatory drug treatment in multiple myeloma patients.
41. Time to Improve Bortezomib and Lenalidomide Lines of Therapy
42. Light Chain Escape in Multiple Myeloma
43. Myeloma MRD by deep sequencing from circulating tumor DNA does not correlate with results obtained in the bone marrow
44. Efficacy, safety, and cost of pomalidomide in relapsed and refractory multiple myeloma
45. Serum free light chains should be the target of response evaluation in light chain multiple myeloma rather than urines
46. Rôle de Tif1gamma dans les différenciations granulo-monocytaire et macrophagique
47. Carfilzomib Weekly Plus Melphalan and Prednisone in Newly Diagnosed Elderly Multiple Myeloma (IFM 2012-03) / 57th Annual Meeting of the American-Society-of-Hematology - Orlando, FL
48. Carfilzomib weekly-melphalan-prednisone in untreated elderly multiple myeloma: IFM2012-03.
49. Carfilzomib Weekly Plus Melphalan and Prednisone in Newly Diagnosed Elderly Multiple Myeloma (IFM 2012-03)
50. Assessment of Mobilization Cost for Multiple Myeloma Using 2 Different Mobilization Strategies: High-Dose Cyclophosphamide Versus Plerixafor. on Behalf of IFM
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.